Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Biosimilars
-
By Donald Zuhn — Earlier this month, the Congressional Budget Office (CBO) issued a report, entitled "Budget Options, Volume I, Health Care," that presents 115 options for changing U.S. health care policy. In the Preface to the report, the CBO states that "[t]he inclusion or exclusion of a particular policy change does not represent…
-
By Donald Zuhn — Patent Docs periodically reports on the lobbying efforts of various players in the biotech/pharma industry (see links below for reports on first and second quarter lobbying this year). Our interest in the lobbying expenditures of these companies and organizations stems from the push by Congress over the past two years…
-
By Donald Zuhn — Last Friday, Medco Health Solutions, Inc. added its name to the list of companies seeking a follow-on biologics (FOB) regulatory pathway (see Reuters report). The endorsement was not entirely surprising given Medco's vested interest — the company, based in Franklin Lakes, NJ, is the nation's largest mail order pharmacy and…
-
By Donald Zuhn — On Tuesday, Alex Brill (at right), a principal at Matrix Global Advisors, LLC and former chief economist to the House Ways and Means Committee, released a white paper which asserts that a follow-on biologics regulatory pathway providing a data exclusivity period of seven years would be "sufficient for maintaining strong incentives…
-
By Donald Zuhn — As part of its ongoing "Conversations With" series, the Washington Legal Foundation (WLF) recently made available its latest question-and-answer offering, which examines the ongoing evolution of intellectual property rights in the United States and internationally. In the paper, entitled "The Changing Legal Landscape For Intellectual Property," former Attorney General and…
-
By Donald Zuhn — Like many Americans, we spent Tuesday evening watching the presidential election returns come in, and now that Senator Barack Obama has been elected the 44th president of the United States, we thought it would be a good idea to take a look back at some of our previous reports discussing…
-
By Donald Zuhn — Last week, Teva Pharmaceutical Industries Ltd. announced that the European Commission’s Directorate General for Enterprise and Industry has granted the company a marketing authorization for its human granulocyte colony stimulating factor (G-CSF) product. Teva had earlier received a favorable opinion for its G-CSF product from the Committee for Medicinal…
-
By Donald Zuhn — Presidential Candidates Support Follow-on Biologics Regulatory Pathway Last week, Forbes.com reported that representatives of Senator Barack Obama's and Senator John McCain's campaigns have indicated that each candidate, if elected, would place the passage of a follow-on biologics regulatory pathway at the top of his health care agenda. The primary…
-
By Donald Zuhn — On Wednesday, Dr. Laurence J. Kotlikoff, a professor of economics at Boston University, released the results of his analysis of the impact of varying lengths of market exclusivity on innovation in the biotechnology sector. The 20-page report, entitled "Stimulating Innovation in the Biologics Industry: A Balanced Approach to Marketing…
-
By Donald Zuhn — Last month, we reported on the lobbying expenditures for fourteen biotech and pharma companies and organizations in the second quarter of 2008. Recent news reports have allowed us to add four more companies to the list: • Sanofi-Aventis’ U.S. subsidiary spent more than $1.2 million on second quarter lobbying…
Patent Docs 